Very important pharmacogene summary ADRB2

Litonjua, Augusto A.; Gong, Li; Duan, Qing; Shin, Jaekyu; Moore, Mariellen J.; Weiss, Scott T.; Klein, Teri E.; Altman, Russ B.

doi:10.1097/fpc.0b013e328333dae6

Cited by 83 publications

(65 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Inter-ethnic differences in this receptor have been proposed to explain differences in responses to drugs such as terbutaline, isoproterenol and albuterol. 23 …”

Section: Discussionmentioning

confidence: 99%

Frequencies of the Arg16Gly, Gln27Glu and Thr164Ile Adrenoceptor β2 Polymorphisms among Omanis

Balushi

Zadjali

Al-Sinani

et al. 2015

SQUMJ

View full text Add to dashboard Cite

“…Inter-ethnic differences in this receptor have been proposed to explain differences in responses to drugs such as terbutaline, isoproterenol and albuterol. 23 …”

Section: Discussionmentioning

confidence: 99%

Frequencies of the Arg16Gly, Gln27Glu and Thr164Ile Adrenoceptor β2 Polymorphisms among Omanis

Balushi

Zadjali

Al-Sinani

et al. 2015

SQUMJ

View full text Add to dashboard Cite

“…Our study demonstrating lack of association of ADRB2 polymorphism with asthma susceptibility is supported by in vivo studies of the genetic variants in ADRB2 which suggests that Arg/Gly polymorphisms are not likely to be disease-causing but possibly serve as predictive markers for responsiveness to beta2-agonists [34]. Furthermore, reports from three meta-analyses of common non-synonymous SNPs in ADRB2 have concluded that the polymorphisms are not associated with the diagnosis of asthma in different ethnic groups [35,36].…”

Section: Discussionmentioning

confidence: 51%

Analysis of ADRB2 (Arg16Gly) Gene Variant with Susceptibility, Pharmacogenetic Response and Disease Severity in South Indian Asthmatics

Jyothy

Marri

et al. 2015

Inflammation

View full text Add to dashboard Cite

β2-Adrenergic receptor (β2-AR) plays a crucial role in asthma pathophysiology by regulating, processes of the lung function, and clinical response to bronchodilators. The +46G>A- Gly16Arg polymorphism in the gene encoding β2 adrenergic receptor (ADRB2) has been associated with receptor non-responsiveness after β2-agonist exposure. In the present study, we sought to evaluate the possible association of Gly16Arg polymorphism with asthma susceptibility, pharmacogenetic response to Salbutamol, and varying degrees of disease severity. Three hundred ninety-eight clinically diagnosed patients and 456 healthy controls were enrolled for the study. Patients were classified into severity classes according to Global Initiative for Asthma guidelines. To assess bronchodilator response, spirometry was performed before and 15 min after Salbutamol (200 μg) delivery. Responders to Salbutamol were categorized if percentage reversibility was greater than or equal to 12% in them, while those showing reversibility less than 12% were classified as non-responders. Genotyping was carried out by ARMS-PCR technique. Statistical methods were applied to test for the significance of the results. In the present study, there was lack of significant association of polymorphism with disease susceptibility as well as with bronchodilator response. The polymorphism was not associated with mild and moderate asthma subtypes; however, there was a notable association with severe asthma subtype. In addition, the polymorphism was associated with severe asthma compared to subtypes of mild and moderate asthma combined. In a South Indian population, the ADRB2 Arg/Gly may not form a susceptible variant to develop asthma nor can be a standard predictive marker to bronchodilator response; nevertheless, the patterns in asthma severity can be predicted by analyzing this variant.

show abstract

“…We are participating in efforts being made by the biocuration community to require inclusion of standard identifiers for variants, such as dbSNP rs number, in publications. We also write detailed online summaries of very important pharmaco genes (41 to date) and their variants, many of which have also been published [14–23]. …”

Section: Presentmentioning

confidence: 99%

Pharmacogenomics and Bioinformatics: Pharmgkb

2010

View full text Add to dashboard Cite

The NIH initiated the PharmGKB in April 2000. The primary mission was to create a repository of primary data, tools to track associations between genes and drugs, and to catalog the location and frequency of genetic variations known to impact drug response. Over the past 10 years, new technologies have shifted research from candidate gene pharmacogenetics to phenotype-based pharmacogenomics with a consequent explosion of data. PharmGKB has refocused on curating knowledge rather than housing primary genotype and phenotype data, and now, captures more complex relationships between genes, variants, drugs, diseases and pathways. Going forward, the challenges are to provide the tools and knowledge to plan and interpret genome-wide pharmacogenomics studies, predict gene–drug relationships based on shared mechanisms and support data-sharing consortia investigating clinical applications of pharmacogenomics.

show abstract

Very important pharmacogene summary ADRB2

Cited by 83 publications

References 66 publications

Frequencies of the Arg16Gly, Gln27Glu and Thr164Ile Adrenoceptor β2 Polymorphisms among Omanis

Frequencies of the Arg16Gly, Gln27Glu and Thr164Ile Adrenoceptor β2 Polymorphisms among Omanis

Analysis of ADRB2 (Arg16Gly) Gene Variant with Susceptibility, Pharmacogenetic Response and Disease Severity in South Indian Asthmatics

Pharmacogenomics and Bioinformatics: Pharmgkb

Contact Info

Product

Resources

About